Primary Intracranial Atypical Teratoid/Rhabdoid Tumors of Infancy and Childhood: MRI Features and Patient Outcomes


AJNR Am J Neuroradiol 2006, 27 (5) 962-971
http://www.ajnr.org/content/27/5/962
Primary atypical teratoid/rhabdoid tumors (AT/RTs) are rare malignant intracranial neoplasms, usually occurring in young children.1-13 They were termed “AT/RT” because they contain nests or sheets of rhabdoid tumor cells as well as varying proportions of primitive neuroectodermal tumor (PNET) cells, mesenchymal spindle-shaped tumor cells, and/or epithelial-type tumor cells.1,3,7,8,11,12 AT/RT has been misdiagnosed in the past as PNET because of frequent overlapping histologic features.1,3-6 AT/RTs can now be distinguished from PNET and other tumors by using specific immunohistochemical markers and by detection of deletions and/or mutations involving the hSNF5/INI1 tumor-suppressor gene in chromosome band 22q11.2.1,3,5-10 These tumors have aggressive growth with high potential for dissemination within the central nervous system (CNS).1,11 Confirmation of the diagnosis of AT/RT is important because the tumors typically have a poor prognosis that is worse than that of PNET/medulloblastoma (MB), necessitating intensive therapy that differs markedly from the treatment for PNET/MB.1,3,4,9,10

The objectives of this study were to characterize the MR imaging features and locations of primary intracranial AT/RT, to determine the frequency of disseminated disease in the CNS at diagnosis and during postoperative surveillance MR imaging, and to assess patient outcomes.
Table 1: Clinical data of 17 patients with atypical teratoid/rhabdoid tumors

<table>
<thead>
<tr>
<th>Patient No./Age (y)/Sex</th>
<th>Tumor Location</th>
<th>Surgical Resection</th>
<th>Disseminated Tumor at Diagnosis/MRI</th>
<th>CSF</th>
<th>Cytology at Diagnosis</th>
<th>Postoperative Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/2/F</td>
<td>Vermis</td>
<td>Total</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>R+C</td>
<td>Dead</td>
</tr>
<tr>
<td>2/4/M</td>
<td>Vermis</td>
<td>Total</td>
<td>–</td>
<td>–</td>
<td>R</td>
<td>R+C</td>
<td>No evident disease</td>
</tr>
<tr>
<td>2/10/M</td>
<td>Vermis</td>
<td>Total</td>
<td>–</td>
<td>–</td>
<td>R</td>
<td>R+C</td>
<td>No evident disease</td>
</tr>
<tr>
<td>4/3/2/M</td>
<td>Cerebellar hemisphere</td>
<td>Subtotal</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>R+C</td>
<td>No evident disease</td>
</tr>
<tr>
<td>5/1/3/M</td>
<td>Midbrain</td>
<td>Biopsy</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>C</td>
<td>Dead</td>
</tr>
<tr>
<td>6/0/8/F</td>
<td>Cerebellum–pons angle cistern</td>
<td>Subtotal</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>C</td>
<td>Dead</td>
</tr>
<tr>
<td>7/5/M</td>
<td>Frontal lobe</td>
<td>Partial</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>R+C</td>
<td>Dead</td>
</tr>
<tr>
<td>8/3/4/F</td>
<td>Frontal lobe</td>
<td>Subtotal</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>R+C</td>
<td>Dead</td>
</tr>
<tr>
<td>9/4/M</td>
<td>Frontal lobe</td>
<td>Partial</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>R+C</td>
<td>Dead</td>
</tr>
<tr>
<td>10/4/F</td>
<td>Septum pelliculum</td>
<td>Subtotal</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>R+C</td>
<td>Dead</td>
</tr>
<tr>
<td>11/0.7/F</td>
<td>Pineal</td>
<td>Subtotal</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>C</td>
<td>Dead</td>
</tr>
<tr>
<td>12/0.3/F</td>
<td>Pineal–midbrain–cerebellum</td>
<td>Biopsy</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>None</td>
<td>Dead</td>
</tr>
<tr>
<td>13/0.8/M</td>
<td>Pineal–midbrain–cerebellum</td>
<td>Biopsy</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>None</td>
<td>Dead</td>
</tr>
<tr>
<td>14/8/F</td>
<td>Vermis</td>
<td>Total</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>R+C</td>
<td>Dead</td>
</tr>
<tr>
<td>15/15/M</td>
<td>Frontal lobe</td>
<td>Total</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>R+C</td>
<td>No evident disease</td>
</tr>
<tr>
<td>16/0.5/M</td>
<td>Pineal</td>
<td>Total</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>C</td>
<td>Dead</td>
</tr>
<tr>
<td>17/2.5/M</td>
<td>Cervical–medullary junction</td>
<td>Partial</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>C</td>
<td>Dead</td>
</tr>
</tbody>
</table>

Note:—CSF indicates cerebrospinal fluid; R, radiation therapy; C, chemotherapy.

Methods

Patient Group

We reviewed the tumor registry files and surgical and pathologic reports from 3 medical centers and found records of 17 patients who had resection of primary intracranial AT/RT from 1991 to 2001. Thirteen patients had preoperative MR imaging examinations of the head. Seventeen patients, including the 13 patients with preoperative MR imaging, had postoperative staging and surveillance MR imaging of the spine and head. The study group consisted of 10 male and 7 female patients (Table 1). At the time of diagnosis, the patients ranged in age from 4 months to 15 years (mean age, 3.7 years; median age, 2.9 years). Fifteen patients (88%) were younger than 7 years at diagnosis, including 8 who were 3 years of age or younger. By surgical report, 6 patients (35%) had gross total resection of AT/RT, 5 (29%) had subtotal resection (> 75% reduction in tumor size), 3 (18%) had partial resection (25%–75% reduction), and 3 (18%) had undergone biopsies. Five patients had undergone postoperative chemotherapy, 1 patient was treated with radiation, and 9 patients experienced both chemotherapy and radiation.

Pathology Reports

Reports from light microscopic studies by neuropathologists at the 3 institutions were reviewed for descriptions of AT/RT with regard to the presence of rhabdoid cells in the specimens as well as necrosis and hemorrhage. To distinguish AT/RT from germ-cell tumors, classic PNETs, and other primary tumors of the CNS, one routinely uses immunoreactivity to specific monoclonal antibodies (epithelial membrane antigen, vimentin, actin, desmin, cytokeratin, glial fibrillary acidic protein, and neurofilament protein) with the immunoperoxidase technique.3 Results from the immunohistochemical analysis for the gene product of the hSNF5/INI1 tumor-suppressor gene were available for 4 tumor samples.7

MR Imaging

MR imaging was performed at 1.5T. Thirteen patients had preoperative contrast-enhanced MR imaging of the head. Multisection spin-echo pulse images were obtained in all MR imaging of the head and included short TR/short TE (400–800/9–22/1–2 [TR/TE/excitation]), long TR/short TE (2000–3200/15–30/1–2), and long TR/long TE (2000–6000/70–132/1–3) images. Fluid-attenuated inversion recovery (FLAIR) (9000–10 000/120–148/2200 [TR/TE/TI] images were obtained in 6 patients. Echo-planar diffusion-weighted images (DWI) were obtained in 4 patients and were acquired with b values of 1000 seconds/mm² in 3 orthogonal gradient directions. Apparent diffusion coefficient (ADC) images were also generated to assess false-positive nondiffusion-related effects on DWI. Single-voxel (n = 1) and multivoxel (n = 2) proton MR spectroscopy was performed on 1 AT/RT before surgery and 2 residual tumors by using spin-echo point-resolved sequences (1000–1600/135–144 [TR/TE]) with volumes of interest ranging from 8 to 16 mL. MR imaging was performed in all patients after IV administration of gadopentetate dimeglumine or gadoteridol (0.1 mmol/kg) by use of short TR/short TE sequences (400–800/11–22/1–2).

The preoperative cranial MR images of AT/RTs were evaluated for location, lesion size, MR signal intensity (low, intermediate, high, or mixed), signal intensity relative to gray matter on FLAIR and long TR/long TE images, contrast-enhancement features (degree: mild, moderate, or prominent; extent: small [less than one third], intermediate [one third to two thirds], or large [more than two thirds]; and pattern: heterogeneous or homogeneous). The presence of disseminated disease in the leptomeninges at diagnosis was assessed. Signal intensity of AT/RTs on DWI and ADC images was compared with that in noninvolved portions of brain parenchyma. Preoperative CT scans were also available for review for 6 patients.

A total of 65 contrast-enhanced postoperative MR imaging studies of the spine and 121 contrast-enhanced postoperative MR imaging studies of the head were reviewed. The unenhanced and contrast-enhanced postoperative short TR images of the spine were evaluated...
for enhancement in the pial-subarachnoid space. Postoperative MR images of the head were evaluated for lesions or abnormal enhancement in the brain parenchyma, ventricles, leptomeninges, and dura. All MR images were reviewed by 2 neuroradiologists with subsequent correlation to the reports of the examinations from each institution.

**CSF Cytologic Analysis**
Results from CSF histopathologic examinations were available for 15 of the 17 patients. A total of 54 CSF samples were obtained after surgery. Thirty-three of the CSF samples were contemporaneous with MR imaging (ie, obtained within 3 weeks of MR imaging examinations; mean, 7.2 days; median, 5 days). Results of CSF histopathologic analysis were compared with those of contemporaneous MR imaging examinations in the assessment for disseminated leptomeningeal tumors and patient outcomes.

**Statistical Methods**
The dates of patients’ deaths were correlated with the initial surgical dates and those of postoperative MR imaging results positive for lesions or abnormal enhancement in the pial-subarachnoid space. Postoperative MR examinations in the assessment for disseminated leptomeningeal tumors and patient outcomes.

Information pertaining to case demographic and clinical data are given in Table 1. Tables 2 and 3 list the immunoreactivity profiles and imaging findings of AT/RT, respectively.

**Pathologic Findings**
All specimens of AT/RT had histologic evidence of rhabdoid cells. Necrosis and hemorrhage were described in the reports of 10 and 4 lesions, respectively. Immunoreactivity results of tumor specimens to monoclonal antibodies are listed in Table 2. Positive reactions of antibodies to vimentin, epithelial membrane antigen (EMA), and actin (which are 3 epitopes typically expressed by rhabdoid tumor cells in AT/RT) were observed in 100%, 100%, and 83%, respectively. Reactivity to the primary neural antibodies, neurofilament protein (NFP), and glial fibrillary acidic protein (GFAP) was observed in 50% and 87%, respectively. Monosomy of chromosome 22 was found in 2 of 3 AT/RTs tested for tumor karyotypes. The other patient had a constitutional ring chromosome 22 with loss of the distal part of the long arm containing the 22q11.2 locus. Deletions and/or mutations of the tumor-suppressor gene hSNF5/INI1 in chromosome 22 were found in all 7 AT/RTs tested. In addition, 3 patients had germ-line mutations involving the hSNF5/INI1 gene, including a 4-month-old patient who had synchronous intracranial AT/RT and a malignant rhabdoid tumor in the left kidney. The intracranial tumor showed immunoreactivity to GFAP and NFP, whereas the malignant renal rhabdoid tumor did not. All 4 AT/RTs tested showed no nuclear staining for the hSNF5/INI1 gene product, indicating inactivation of both hSNF5/INI1 tumor-suppressor genes.

**Tumor Location**
The locations of AT/RTs are listed in Table 1. Eight (47%) of AT/RTs were infratentorial (Figs 1–3), 7 (41%) were supratentorial (Figs 4, 5), and 2 were both infra- and supratentorial (Fig 6). The locations of AT/RTs were infratentorial (Figs 1–3), 7 (41%) were supratentorial (Figs 4, 5), and 2 were both infra- and supratentorial (Fig 6).

### Table 3: Preoperative MR imaging data of 13 patients with atypical teratoid/rhabdoid tumors

<table>
<thead>
<tr>
<th>Patient No./Age/Sex</th>
<th>Tumor Location</th>
<th>Tumor Size (cm)</th>
<th>Hemorrhage</th>
<th>Cyst/Necrosis</th>
<th>Long TR/Long TE (T2WI)</th>
<th>FLAIR</th>
<th>ADC</th>
<th>Postgadolinium</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/2/F</td>
<td>Vermis</td>
<td>3 × 3 3 × 3.5</td>
<td>–</td>
<td>+</td>
<td>1+</td>
<td>iso</td>
<td>homo</td>
<td>3+/heterogeneous</td>
</tr>
<tr>
<td>2/4/M</td>
<td>Vermis</td>
<td>4 × 3 4 × 3.4</td>
<td>–</td>
<td>+</td>
<td>1+</td>
<td>iso</td>
<td>1+</td>
<td>2+/heterogeneous</td>
</tr>
<tr>
<td>3/10/M</td>
<td>Vermis</td>
<td>3.8 × 4 3.8 × 4</td>
<td>+</td>
<td>+</td>
<td>1+</td>
<td>iso</td>
<td>1+</td>
<td>1+/heterogeneous</td>
</tr>
<tr>
<td>4/3.2/M</td>
<td>Cerebellar hemispheres</td>
<td>2.8 × 3 3 × 3</td>
<td>–</td>
<td>+</td>
<td>1+</td>
<td>iso</td>
<td>1+</td>
<td>3+/heterogeneous</td>
</tr>
<tr>
<td>5/1.3/M</td>
<td>Midbrain</td>
<td>1.2 × 1.3 1.2 × 1.2</td>
<td>–</td>
<td>–</td>
<td>1+</td>
<td>1+</td>
<td>3+/heterogeneous</td>
<td></td>
</tr>
<tr>
<td>6/0.8/B/F</td>
<td>Cerebellum–pontine angle cistern</td>
<td>3 × 3 3.2 × 3</td>
<td>–</td>
<td>+</td>
<td>iso</td>
<td>iso</td>
<td>3+/heterogeneous</td>
<td></td>
</tr>
<tr>
<td>7/5/M</td>
<td>Frontal lobe</td>
<td>6 × 6 6.5 × 9</td>
<td>–</td>
<td>+</td>
<td>iso</td>
<td>iso</td>
<td>3+/heterogeneous</td>
<td></td>
</tr>
<tr>
<td>8/3.4/F</td>
<td>Frontal lobe</td>
<td>5.2 × 4 5.8 × 6</td>
<td>–</td>
<td>+</td>
<td>iso</td>
<td>iso</td>
<td>Decreased 3+/heterogeneous</td>
<td></td>
</tr>
<tr>
<td>9/4/M</td>
<td>Frontal lobe</td>
<td>4.2 × 7 6.5 × 6</td>
<td>+</td>
<td>+</td>
<td>iso</td>
<td>3+/heterogeneous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10/4/F</td>
<td>Septum</td>
<td>3.8 × 3 3.4 × 3.8</td>
<td>–</td>
<td>+</td>
<td>iso</td>
<td>1+</td>
<td>1+/heterogeneous</td>
<td></td>
</tr>
<tr>
<td>11/0.7/F</td>
<td>Pineal</td>
<td>2 × 2 2.5 2 × 2.5</td>
<td>+</td>
<td>+</td>
<td>iso</td>
<td>Decreased none</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12/0.3/F</td>
<td>Pinea–midbrain– cerebellum</td>
<td>4 × 3 3.2 × 2.2</td>
<td>+</td>
<td>+</td>
<td>1+</td>
<td>1+</td>
<td>1+/heterogeneous</td>
<td></td>
</tr>
<tr>
<td>13/0.8/M</td>
<td>Pinea–midbrain– cerebellum</td>
<td>3.5 × 2 2.8 × 2.8</td>
<td>–</td>
<td>+</td>
<td>1+</td>
<td>3+/heterogeneous</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Signal intensity on T2WI and FLAIR refers signal of atypical teratoid/rhabdoid tumors relative to gray matter with iso (isointense) indicating the same as and 1+ and 2+ being progressively higher in signal. Apparent diffusion coefficient (ADC) of the atypical teratoid/rhabdoid tumors is listed relative to normal uninvolved gray matter. For postgadolinium contrast enhancement, none indicates no enhancement and 1+, 2+, and 3+ represent progressively greater degrees of enhancement.
tentorial (12%) via contiguous extension (Fig 6). The cerebellum was the most frequent infratentorial location. The 2 lesions that were both infra- and supratentorial primarily involved the pineal gland and dorsal midbrain, with some extension into the cerebellum (Fig 6). Of the supratentorial lesions, the frontal lobe was the most frequent site (Fig 4). AT/RT is typically intra-axial (94%) except for 1 extra-axial lesion located in the cerebellopontine angle cistern (Fig 7).

At surgery, the extra-axial lesion was found to extend into the porus acousticus and was adherent to the dura laterally, the seventh and eighth cranial nerves inferiorly, and the brain stem medially. Intraventricular extension of primary AT/RT was found into the third ventricle (n = 1), fourth ventricle (n = 3), third and fourth ventricles (n = 2), and lateral ventricle (n = 1) (Figs 1, 2, 5, and 6). At the time of diagnosis and initial staging, 4 (24%) of 17 patients had MR im-

Fig 1. MR images of a 2-year-old girl with a germ-line mutation of the hSNF5/INI1 gene and AT/RT in the vermis extending into the fourth ventricle.
A, Sagittal (TR/TE, 520/10) MR image shows the tumor to have intermediate and low signal intensity. The tumor invades the dorsal brain stem.
B, Axial (TR/TE, 5700/90) MR image shows the tumor to have heterogeneous intermediate-to-slightly-high signal intensity that is slightly hyperintense relative to gray matter, as well as zones of high signal intensity representing cystic/necrotic regions. Abnormal high signal intensity is also seen in the dorsal pons and left middle cerebellar peduncle, consistent with tumor invasion.
C, Axial (TR/TE, 880/22) MR image shows the tumor to have solid-enhancing and nonenhancing cystic/necrotic components. Irregular enhancing margins of the lesion are seen at the dorsal pons and left middle cerebellar peduncle, consistent with tumor invasion. This patient died 1.6 years after diagnosis from locally recurrent and disseminated tumor.
D, Axial CT image shows the solid portion of the AT/RT to have attenuation slightly higher than that of gray matter. Low-attenuation cystic/necrotic zones and several tiny calcifications are also present.

Fig 2. MR images of a 10-year-old boy with AT/RT in the vermis, extending into the fourth ventricle.
A, Axial (TR/TE, 600/11) MR image shows the tumor to have mixed intermediate signal intensity as well as irregular zones of high signal intensity secondary to hemorrhage (methemoglobin).
B, Axial (TR/TE, 3500/108) MR image shows the tumor to have heterogeneous mixed low, intermediate, and high signal intensity.
C, Axial (TR/TE, 500/29) MR image shows contrast enhancement in less than two thirds of the AT/RT. This patient is alive without evidence of disease 9 years after surgery/initial diagnosis.

Fig 3. MR images of a 1.3-year-old boy with AT/RT in the right cerebral peduncle.
A, Axial (TR/TE, 600/10) MR image shows the tumor to have intermediate signal intensity.
B, Axial (TR/TE, 4000/105) MR image shows the tumor to have heterogeneous intermediate-to-slightly-high signal intensity, which includes zones that are isointense or slightly hyperintense to gray matter.
C, Axial (TR/TE, 700/22) fat-suppressed MR image shows prominent homogeneous contrast enhancement of the primary lesion as well as abnormal subarachnoid enhancement in the interpeduncular cistern and along the sulci adjacent to frontal lobes (arrow), representing disseminated leptomeningeal tumor. This patient died 4 months after diagnosis.
aging evidence of disseminated tumor in the leptomeninges (Fig 3). One patient had evidence of tumor in the intracranial leptomeninges, and 3 had evidence of disseminated tumor in both the spinal and intracranial leptomeninges. A 4-month-old patient with intracranial AT/RT involving the pineal gland, tectal plate, and vermis (Fig 6) also had a contemporaneous malignant rhabdoid tumor in the left kidney.

**Tumor Size**

At diagnosis, AT/RTs ranged from 1.2 to 6 cm superoinferiorly (mean, 3.6 cm; median, 3.7 cm) by 1.3–7 cm transversely (mean, 3.8 cm; median, 3.6 cm), and by 1.2–9 cm anteroposteriorly (mean, 3.9 cm; median, 3.3 cm) (Table 3). The smallest tumor was located in the midbrain (Fig 3), and the largest lesions were located in the frontal lobe (Fig 4).
Preoperative MR Imaging Signal-Intensity Characteristics

**Short TR/Short TE Images.** On short TR images, AT/RT typically had heterogeneous intermediate signal intensity with zones of low (n = 7), high (n = 1), or both low and high (n = 4) signal intensity, resulting from cystic and/or necrotic regions, hemorrhage, or both, respectively (Figs 1, 2, 4, 5, and 7). Foci of high signal intensity secondary to methemoglobin were small except for 1 lesion in the inferomedial left frontal lobe (Figs 2 and 4). One of the hemorrhagic lesions was initially thought to have been a hemorrhagic infarct versus hemorrhage secondary to a cavernous angioma (Fig 4). Subsequent MR imaging 7 months later showed a large intra-axial lesion involving both frontal lobes (Fig 4).

**FLAIR Images.** FLAIR images of AT/RT before surgery were available for review for 6 patients. Solid portions of AT/RT had intermediate signal intensity that was isointense (n = 4), isointense and slightly hyperintense (n = 1), or slightly hyperintense (n = 1) relative to gray matter (Figs 8 and 9 and Table 3).

**Long TR/Long TE Images.** On long TR/long TE images, solid portions of AT/RT typically had heterogeneous intermediate-to-slightly-high signal intensity that was isointense (n = 6), or slightly hyperintense (n = 7), and mixed isointense and slightly hyperintense relative to gray matter (Figs 1–6, 8, 9 and Table 3).

Small zones of low signal intensity were also seen in 5 lesions secondary to blood products (n = 4) or calcifications (n = 1) (Figs 2 and 4). Zones of high signal intensity comparable to CSF were seen in 12 of 13 tumors secondary to cystic/necrotic zones with (n = 5) or without (n = 7) hemorrhage (Figs 1, 2, 4–6, 8, 9). Cystic and/or necrotic tumor zones were <2 cm in 8 patients and >2 cm in 4 patients. Signal intensity heterogeneity was related to the relative proportions of cystic/necrotic zones and/or hemorrhage that were also seen on the short TR images. Reports from light microscopy of tumor samples described histologic findings of necrosis and hemorrhage in 10 and 4 of the tumors, respectively.

**DWI and ADC Images.** Four patients in this series had preoperative MR imaging that included DWI and ADC imaging. All 4 of these AT/RTs showed hyperintense signal intensity on DWI and hypointense signal intensity on ADC images relative to normal brain parenchyma, indicating restricted diffusion within these tumors (Fig 9 and Table 3).

**Proton MR Spectroscopy.** Proton MR spectra were available for review for 1 AT/RT before surgery and for 2 residual tumors after partial resection. All 3 AT/RTs showed elevated levels of choline and decreased N-acetylaspartate.

**CT Images.** Preoperative CT scans were available for review for 6 patients. Solid portions of the lesions had intermediate attenuation similar to (n = 3) or slightly higher (n = 3) than that of gray matter (Figs 1 and 4). Zones of low attenuation secondary to cystic necrotic changes were seen in all 6 AT/RTs. Calcifications were observed in 3 of the 6 lesions scanned with CT (Fig 4).

**Findings on Contrast-Enhanced MR Images.** All except 1 AT/RT showed contrast enhancement (Fig 8). Regarding the 12 AT/RT that showed contrast enhancement, the fraction of tumor volume showing enhancement was greater than two thirds in 7 patients (58%), between one third and two thirds in 4 (33%), and less than one third in 1 (9%) (Figs 1–7, 9). The enhancement pattern was most often heterogeneous (n = 11, 84%), and homogeneous in only one (6%). Portions of the enhancing margins of AT/RT were ill-defined in 3 patients (Figs 2 and 4). Abnormal enhancement in the intracranial leptomeninges representing disseminated tumor was found in 4 patients at the time of diagnosis (Fig 3).
Patient Outcomes and Findings on Postoperative Contrast-Enhanced MR Images. Thirteen patients (76%) have died from 1 month to 12.5 years (mean, 2.3 years; median, 1.3 years) after diagnosis. Only 3 of the 13 patients who died had undergone gross total resections (Table 1). Other factors associated with a poor prognosis were young age at diagnosis and presence of disseminated leptomeningeal tumor. Patients who died had mean and median ages of 2.4 and 1.7 years at diagnosis, respectively, compared with the surviving patients whose mean and median ages were 8.1 and 7 years at diagnosis, respectively \((P = .009, \text{Mann-Whitney } U \text{ test})\). Ten of the 13 deceased patients had MR imaging evidence of disseminated leptomeningeal tumor at the time of diagnosis \((n = 4)\) or in the subsequent postoperative period \((n = 6)\). The 4 patients who had disseminated tumor in the leptomeninges at diagnosis died from 4 months to 5.1 years (mean, 2.1 years) later. Only 1 of these patients had a reported gross total resection of the primary tumor. The other 6 deceased patients with disseminated disease had evidence of subarachnoid tumor on MR images from 3 months to 2.8 years (mean, 1.1 years) after surgery and earlier negative findings on imaging examinations. Only 2 of these patients had gross total resection of the primary tumors. These 6 patients also had MR imaging evidence of residual or locally recurrent tumor before \((n = 3)\), contemporaneous with \((n = 2)\), or after \((n = 1)\) detection of disseminated leptomeningeal tumor with MR imaging. One of these patients also had extension of disseminated intracranial subarachnoid tumor into the peritoneal cavity via a ventricu-
loperitoneal shunt. The presence of disseminated leptomeningeal tumor seen with MR imaging was significantly associated with patients’ deaths (P = .002, Fisher exact test). For patients who died with MR imaging evidence of leptomeningeal tumor, contemporaneous CSF cytology was positive in 56%. None of the patients who died had CSF cytology positive for tumor cells without MR imaging evidence of disseminated tumor.

Of the 3 remaining deceased patients, 1 died from sepsis related to immunosuppression from chemotherapy. Another patient was a 4-month-old female infant with a germ-line mutation who had intracranial AT/RT as well as a malignant rhabdoid tumor in the left kidney. This patient died 6 weeks after diagnosis of metastatic pulmonary lesions from the malignant renal rhabdoid tumor (Fig 6). The third patient was 3.4 years old at diagnosis and died 12.5 years later after 3 local recurrences, despite 3 surgeries and multiple cycles of chemotherapy.

The 4 patients who are alive have follow-up intervals ranging from 4 to 11.5 years (mean, 8.4 years; median, 9 years) after surgery. Surviving patients ranged from 3.2 to 15 years at the time of diagnosis. Three surviving patients had gross total surgical resection, and the other had a subtotal resection. One of the surviving patients had postsurgical radiation, and 3 had both radiation and chemotherapy. The 3 patients who had gross total resections have had no evidence of residual or locally recurrent tumor or disseminated neoplasm by MR imaging or CSF cytology in follow-up periods ranging from 4 to 11.5 years (mean, 8.5 years) after surgery. The single surviving patient who had a subtotal resection has been disease-free 7 years after a complete response for minimal residual local disease.

Discussion

AT/RTs are rare malignant intracranial tumors, representing only 1.3% of primary CNS tumors in the pediatric population and 6.7% of CNS tumors in children younger than 2 years. Malignant rhabdoid tumors can occur in many locations in the body, though the kidney and CNS are the most common primary sites. Within the CNS, 38%–65% have been reported to be infratentorial, 27%–62% in supratentorial locations, and 4%–8% occurring in multiple CNS sites at diagnosis.

Rhabdoid cells in AT/RT observed with light microscopy are often plump with eccentric round nuclei containing prominent nucleoli within fibrillar or granular eosinophilic cytoplasm, though rhabdoid tumor cells can also be small and spindle-shaped with ovoid nuclei or large, containing nuclei with wrinkled margins. Abundant mitotic figures, necrosis, hemorrhage, and ill-defined margins with adjacent brain are common histologic feature seen in AT/RT. In addition to the rhabdoid tumor cells, intracranial AT/RTs often contain varying percentages of PNET cells, malignant mesenchymal spindle-shaped cells, and cells with epithelial differentiation. The presence of these diverse elements accounts for naming these neoplasms “AT/RT.” Despite the presence of multiple cellular elements in these tumors, AT/RTs lack germ cell and tissue differentiation associated with malignant teratomas. In addition, AT/RTs do not show immunoreactivity to epitopes associated with germ cell tumors such as human chorionic gonadotropin, placental alkaline phosphatase, and alpha-fetoprotein. Up to 70% of AT/RTs contain areas that histologically resemble PNET. This latter feature has caused erroneous diagnosis of AT/RT as PNET in the past. Positive reactions to neural antibodies such as neurofilament protein and glial fibrillary acid protein may be present in both PNET and AT/RT. Rhabdoid cells in AT/RT, however, typically express epithelial membrane antigen, vimentin, and smooth-muscle actin, which can provide discrimination from PNET and germ cell tumors. Epithelial cells express keratin, whereas desmin is often expressed in the mesenchymal components.

A variety of cytogenetic abnormalities involving chromosome 22 have been found in AT/RT, typically resulting in monosomy 22 or deletions involving band 22q11.2. Deletion of 22q11.2, most often detected by fluorescence in situ hybridization, results in loss of the hSNF5/INI1/SRM28/BAF47 gene. Molecular genetic analysis of tumor tissue demonstrates deletion and/or mutation of hSNF5/INI1 in approximately 70% of AT/RTs. Inactivation of this gene is also diagnostic of rhabdoid tumors of the kidney and other extrarenal sites. The hSNF5/INI1 gene codes for an essential component of the SWI/SNF ATP-dependent chromatin remodeling complex. Functional studies have shown that hSNF5/INI1 may activate and repress target genes, though the specific role of this gene in tumor suppression has not yet been elucidated. In our study we had deletions and/or mutations of this tumor-suppressor gene, and all 4 patients tested had loss of nuclear expression of the protein by immunohistochemistry, confirming the diagnosis of AT/RT.

In addition to acquired somatic mutations involving the hSNF5/INI1 gene in AT/RT, germ-line mutations of this gene have also been reported in some patients, including those with synchronous intracranial AT/RT and renal and/or other extrarenal malignant rhabdoid tumors. Germ-line mutations or deletions result in predisposition to developing these malignant tumors at 1 or more sites. In our series who had contemporaneous intracranial AT/RT and a malignant renal rhabdoid tumor was found to have a germ-line mutation of the hSNF5/INI1 gene. Despite the fact that both the intracranial AT/RT and the malignant renal rhabdoid tumor had inactivation of both hSNF5/INI1 tumor-suppressor genes; the intracranial tumor contained rhabdoid, PNET, epithelioid, and mesenchymal tumor cells and showed immunoreactivity to GFAP and NFP, whereas the renal tumor contained only rhabdoid tumor cells and was not immunoreactive to GFAP and NFP. These differing features indicate that these 2 tumors are distinct primary lesions rather than metastases, because the latter would have similar histologic features and immunohistochemical profiles. Germ-line mutations involving the hSNF5/INI1 gene have also been reported in monozygotic twins. One twin had disseminated AT/RT, and the other had a tumor mimicking medulloblastoma with immunoreactivity to vimentin and epithelial membrane antigen. It has been recommended that patients with demonstrated mutations of the hSNF5/INI1 gene in AT/RT have analysis of blood samples to exclude the possibility and implications of constitutional mutations.

The preoperative MR imaging signal-intensity characteristics on short TR and long TR/long TE images and contrast-enhancement features of AT/RTs were usually nonhomogeneous, secondary to the heterogeneous cellular populations in these tumors as well as the frequent presence of necrosis, hemorrhage, and/or calcifications. Similar MR imaging findings have been reported in multiple prior small series of intracranial AT/RT.\(^{21-36}\) Solid portions of AT/RT typically had intermediate-to-slightly-high signal intensity on FLAIR and long TR/long TE images that were isointense and/or slightly hyperintense relative to gray matter. In addition, AT/RTs were shown to have restricted diffusion. The MR imaging findings for AT/RT on long TR/long TE, FLAIR, and DWI are similar to those reported for PNET and are likely related to overlapping histologic features of these hypercellular tumors containing neoplastic cells with high nuclear-to-cytoplasmic ratios and small extracellular spaces.\(^{37,38}\) These MR imaging features for AT/RT and PNET have been reported to occur infrequently in other primary pediatric glial tumors involving the brain.\(^{27}\)

In the current study, calcifications within AT/RT were seen in half of the patients who underwent preoperative CT. Similar CT findings have been reported previously.\(^{27,29,32}\) AT/RTs show various patterns and degrees of gadolinium contrast enhancement, which are features that have been reported for PNET.\(^{38,39}\) In addition, the proton MR spectra of AT/RT and PNET typically show elevated levels of choline and decreased N-acetylaspartate.\(^{38,40}\) Similarities of many imaging features of AT/RT with PNET likely prevent reliable discrimination of these neoplasms based solely on MR imaging data.

The presence of disseminated leptomeningeal tumor at diagnosis/staging and later has been associated with a poor prognosis in patients with AT/RT.\(^ {1,3,5,10,20}\) Leptomeningeal dissemination of tumor at diagnosis/initial staging has been previously reported in 21%–34% of patients with AT/RT by using myelography or gadolinium-enhanced MR imaging and CSF cytology.\(^ {5,9,10}\) Subsequent data from the Children's Cancer Group and AT/RT registry have suggested that the incidence of leptomeningeal dissemination at diagnosis/initial staging is approximately 15%.\(^ {20}\) In the current report, disseminated tumor in the leptomeninges was seen with MR imaging in 24% of patients at diagnosis/initial staging and occurred in another 35% from 4 months to 2.8 years (mean, 1 year) after surgery and earlier imaging examinations with negative findings. Similar frequencies of disseminated tumor have been reported for PNET/MB.\(^ {38,41}\) Ten of the 13 patients with AT/RT who died had MR imaging evidence of disseminated leptomeningeal tumor, including 7 (54%) with residual postoperative tumor. Five patients who died also had progressive enlargement of residual or locally recurrent tumor documented with MR imaging. Similar relapse and disease progression patterns of intracranial AT/RT after surgery have been reported.\(^ {1,3,9,10}\) CSF cytology was positive in only 56% of patients with MR imaging evidence of disseminated leptomeningeal tumor who died. These results are similar to those of a previous report that found that postoperative MR imaging had greater diagnostic accuracy in the early detection of disseminated leptomeningeal medulloblastoma, compared with CSF cytology.\(^ {41}\)

The prognosis of patients with AT/RT is dismal, with reported mean survival rates in the range of 6–15 months.\(^ {1,3,5,9,10,20}\) Gross total resection has been suggested to improve median patient survival rates, compared with those having lesser resection.\(^ {20}\) Gross total or near-complete resections of AT/RT, however, can be performed in fewer than half of patients with AT/RT because of large tumor sizes at diagnosis in young patients and surgically challenging locations.\(^ {9,20}\) Patients with intracranial AT/RT have been treated with different chemotherapy protocols, which have been mostly ineffective.\(^ {1,3,5,9,10,20}\) Moderate responses of AT/RT to high-dose myeloablative chemotherapy followed by autologous bone marrow transplantation or stem cell rescue have been observed, though long-term outcome data are not available.\(^ {20}\) Older patients who received chemotherapy and radiation therapy have a higher likelihood of survival compared with those who received chemotherapy alone.\(^ {20}\) Packer et al\(^ {20}\) reported that there is no effective treatment for children with disseminated AT/RT at diagnosis or for those with tumors initially nonresponsive to chemotherapy.\(^ {20}\) Multi-institutional treatment protocols specifically designed for AT/RT are in development within the Children’s Oncology Group.\(^ {20}\)

Conclusion

AT/RTs are rare malignant intracranial neoplasms usually occurring in young children. AT/RTs have aggressive growth with high potential for dissemination within the CNS. These tumors have been misdiagnosed in the past as PNET/MB because of frequent overlapping histologic and imaging features. AT/RT can now be distinguished from PNET/MB by using specific immunohistochemical markers (EMA, vimentin, actin, hSNF5/INI1) and mutation analysis. Confirmation of the diagnosis of AT/RT is important because these tumors typically have a poor prognosis that is worse than that in PNET/MB, necessitating new intensified therapies. AT/RT was found to be mostly intra-axial (94%) except for 1 extra-axial lesion seen in the cerebellopontine angle cistern. AT/RT can be infratentorial or supratentorial. The unenhanced and enhanced MR imaging features of AT/RT are often variable secondary to cystic/necrotic changes and/or hemorrhage. Disseminated tumor in the leptomeninges was seen with MR imaging in 24% of patients at diagnosis/initial staging and occurred in another 35% from 4 months to 2.8 years after surgery and earlier imaging examinations with negative findings. The overall 1-year and 5-year survival probabilities were 71% and 28%, respectively. Factors associated with poor prognosis were young age at diagnosis (P = .009) and MR imaging evidence of disseminated leptomeningeal tumor (P = .002).

References


